Troluce Capital Advisors LLC Takes Position in GH Research PLC $GHRS

Key Points

• Troluce Capital Advisors LLC has acquired 155,597 shares of GH Research PLC, valued at approximately $1.72 million, representing about 0.5% of its holdings.
• Several large investors increased their stakes in GH Research during the last quarter, with notable boosts from Northern Trust Corp and Woodline Partners LP.
• GH Research reported a quarterly EPS of ($0.15), surpassing analysts' expectations, and has a consensus rating of "Moderate Buy" with a price target of $32.00.

Troluce Capital Advisors LLC bought a new position in shares of GH Research PLC (NASDAQ:GHRS - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 155,597 shares of the company's stock, valued at approximately $1,716,000. GH Research accounts for approximately 0.5% of Troluce Capital Advisors LLC's holdings, making the stock its 19th biggest holding. Troluce Capital Advisors LLC owned about 0.30% of GH Research at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of GHRS. BNP Paribas Financial Markets acquired a new position in shares of GH Research during the 4th quarter worth about $44,000. Two Sigma Investments LP acquired a new position in shares of GH Research during the 4th quarter worth about $117,000. Palumbo Wealth Management LLC acquired a new position in shares of GH Research during the 1st quarter worth about $142,000. Millennium Management LLC acquired a new position in shares of GH Research during the 4th quarter worth about $145,000. Finally, XTX Topco Ltd acquired a new position in shares of GH Research in the 1st quarter valued at approximately $169,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GHRS has been the subject of several research analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $39.00 price objective on shares of GH Research in a research report on Tuesday, June 24th. Zacks Research lowered GH Research from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 13th. Cantor Fitzgerald initiated coverage on GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of GH Research in a research report on Friday, May 9th. Finally, Guggenheim decreased their price objective on GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

GH Research Stock Performance

NASDAQ GHRS traded up $0.04 during trading on Friday, hitting $14.09. The stock had a trading volume of 245,365 shares, compared to its average volume of 195,288. The company has a market capitalization of $733.10 million, a PE ratio of -19.04 and a beta of 0.97. The company's 50-day moving average price is $14.18 and its two-hundred day moving average price is $12.12. GH Research PLC has a 12 month low of $6.00 and a 12 month high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, equities analysts anticipate that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).